Clinical Trial Update: Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating zoledronic acid for aromatase inhibitor-induced musculoskeletal symptoms in breast cancer patients has completed with posted r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Ductal Carcinoma in Situ
• Estrogen Receptor-positive Breast Cancer
• Progesterone Receptor-positive Breast Cancer
• Stage Iiia Breast Cancer
• Stage Iiib Breast Cancer
• Stage Iiic Breast Cancer

Drugs mentioned

• Zoledronic acid (Zoledronic acid)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Ductal Carcinoma in Situ, Estrogen Receptor-positive Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2017-01-09